Spies Christian, Timmermanns Ines, Schräder Rainer
Rush University Medical Center, Section of Cardiology, 1653 W Congress Parkway, Chicago, IL 60612, USA.
Clin Res Cardiol. 2007 Jun;96(6):340-6. doi: 10.1007/s00392-007-0502-3. Epub 2007 Feb 26.
Transcatheter closure of secundum atrial septal defects (ASD) with the Amplatzer septal occluder (ASO) has become a standard procedure in most pediatric and adult patients. However, data addressing success rates and outcome in adults is limited. We sought to define the safety profile of the ASO in the community setting and identify the percentage of adults with ASD amenable to percutaneous closure with the ASO.
We performed a retrospective analysis of patients' records referred for transcatheter ASD closure from 1999 through 2005 at a single institution. Patients were evaluated with right heart catheterization and underwent closure of the ASD according to standard indications under transesophageal and fluoroscopic guidance.
Two hundred and seven consecutive patients were taken to the catheterization laboratory for hemodynamic evaluation and possible interventional closure of an ASD. Of those patients, 18 were excluded because the defect and the left-to-right shunt were hemodynamically insignificant (n = 7) or because there was no distinct defect, but instead a multi-perforated septum (n = 11). Nineteen cases were excluded for anatomic reasons. Of the remaining 170 patients, ASO implantation was attempted and successfully performed in 166 (83% of 200 patients with hemodynamically significant ASD). Complications occurred in 11 cases (6.5%) (device dislocation = 4, transient ST-segment elevation = 4, TIA = 1, hemoptysis = 1, pericardial effusion = 1); none of these events were associated with long-term sequelae. During a median follow-up period of 13 months (range 6-80) there were no major clinical events.
More than 80% of adults with a distinct, hemodynamically significant secundum ASD can be successfully treated with the ASO. The immediate success rates are excellent and follow-up data suggest that the ASO is a safe device well suited for transcatheter ASD closure.
使用Amplatzer房间隔封堵器(ASO)经导管闭合继发孔型房间隔缺损(ASD)已成为大多数儿科和成年患者的标准治疗方法。然而,关于成人患者成功率和治疗结果的数据有限。我们试图确定ASO在社区环境中的安全性,并确定适合用ASO进行经皮闭合的成人ASD患者的比例。
我们对1999年至2005年在一家机构接受经导管ASD闭合治疗的患者记录进行了回顾性分析。患者接受右心导管检查,并在经食管和荧光透视引导下根据标准指征进行ASD闭合。
207例连续患者被送往心导管实验室进行血流动力学评估及可能的ASD介入闭合治疗。其中,18例因缺损及左向右分流在血流动力学上不显著(n = 7)或因无明显缺损而是多孔间隔(n = 11)被排除。19例因解剖学原因被排除。在其余170例患者中,尝试植入ASO并在166例中成功实施(200例血流动力学显著的ASD患者中的83%)。11例(6.5%)发生并发症(装置移位 = 4例,短暂性ST段抬高 = 4例,短暂性脑缺血发作 = 1例,咯血 = 1例,心包积液 = 1例);这些事件均未导致长期后遗症。在中位随访期13个月(范围6 - 80个月)内未发生重大临床事件。
超过80%有明显、血流动力学显著的继发孔型ASD的成人患者可用ASO成功治疗。即刻成功率很高,随访数据表明ASO是一种非常适合经导管闭合ASD的安全装置。